tapebrief
BAX · Q3 2025
BAX · Q1 2026

BAX · Q4 2025 Earnings

Bearish

Baxter International

Reported February 12, 2026

30-second summary

Baxter beat its own Q4 operational growth guide (+3% vs. -2% guided) but missed adjusted EPS at $0.44 vs. $0.52–$0.57 guided, and then dropped a FY2026 adjusted EPS guide of $1.85–$2.05 — a ~16% midpoint cut against FY2025's $2.27 actual. The Novum LVP ship-and-install hold is now explicitly extended for the full year 2026, organic sales are guided approximately flat, adjusted operating margin steps down to 13–14% (from FY2025's implied ~14.5%), and the investor day has been shelved. The Q3 "reset" was not the reset — this is.

Headline numbers

EPS

Q4 FY2025

$0.44

Revenue

Q4 FY2025

$2.97B

+8.0% YoY

Gross margin

Q4 FY2025

19.4%

Operating margin

Q4 FY2025

-24.5%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$2.97B+8.0%$2.83B+4.9%
EPS$0.44—$0.69-36.2%
Gross margin19.4%—33.5%-1410bps
Operating margin-24.5%—6.1%-3060bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
Adjusted EPSQ4 FY2025$0.52 to $0.57$0.44-$0.08 to -$0.13 below guideMissed
Sales Growth (Reported Basis)Q4 FY2025approximately 2%8%+6 percentage points above guideBeat
Sales Growth (Operational Basis)Q4 FY2025decline approximately 2%3%+5 percentage points above guideBeat
Adjusted EPSFY2025$2.35 to $2.40$2.27below high end but near bottomMet

New guidance

MetricPeriodGuideYoY
Adjusted EPSFY2026$1.85 to $2.05-18.5% to -12.3%
Reported Sales GrowthFY2026flat to 1%—
Organic Sales GrowthFY2026approximately flat—
Adjusted Operating MarginFY202613% to 14%—
Non-Operating ExpensesFY2026$280 million to $300 million—
Tax RateFY202618.5% to 19.5%—
Diluted Share CountFY2026approximately 518 million shares—
TSA Income and Other ReimbursementsFY2026$130 million to $140 million—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Medical Products & Therapies$1.388B+6.0%
Healthcare Systems & Technologies$0.827B+5.0%
Pharmaceuticals$0.668B+4.0%
Infusion Therapies & Technologies$1.06B+4.0%
Advanced Surgery$0.328B+12.0%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
U.S. Sales$1.55B+3.0%
International Sales$1.42B+14.0%
Adjusted Operating Income$352 million—
Adjusted Gross Margin35.5%—
Operational Sales Growth3%—
U.S. Operational Sales Growth-1%—
International Operational Sales Growth8%—

Management tone

Q1 "execution on track" → Q2 "prudent downside" → Q3 "reset and stabilize" → Q4 "early-stage turnaround."

The "reset" framing of Q3 was not the reset — Q4 reframes the situation as an early-stage turnaround requiring years, not quarters. Through Q1 and Q2 management defended the existing strategy; Q3 introduced a new CEO posture of dissatisfaction. This quarter Hider went further: "we are in the early stages of a turnaround and have more work to do to deliver strategically, operationally and commercially, and recognize that it will take time to implement real long-term solutions." The investor day has now been postponed. Investors who expected Q3 to mark the bottom now have to underwrite a multi-year recovery with FY2026 explicitly guided to organic flat.

Novum LVP went from "beyond year-end with no timeline" (Q3) to "the ship and installation hold will remain in place for the full year" (Q4). In Q3, customers were initiating returns to Spectrum IQ. This quarter Hider said "we saw a more modest net impact from Novum IQ large volume pump customer returns, which was favorable to results. While responses have varied, in general, customers are waiting for additional clarity on the nature and timing of the additional corrections." The two readings co-exist: short-term financial bleeding has slowed, but the regulatory/quality timeline now stretches through all of 2026 with no resolution path. The customer-attrition window is officially open for a third year.

IV solutions reframed from "structural conservation through 2026" (Q3) to "new baseline" (Q4). Q3 used the 2017 precedent and said conservation was likely to persist into 2026; this quarter Grady said: "we believe that the market is at a new baseline in our IV solutions business." "New baseline" is a permanent reset, not a recovery curve. Combined with H1 absorption headwinds from high-cost inventory produced in H2 2025, this means the IV-solutions margin issue is no longer transient — it is the model.

Restructuring tone shifted from "stabilization" (Q3) to "de-layering with accountability" (Q4). Hider announced removing the segment management layer and embedding commercial, R&D, manufacturing, medical, and functional support directly in each business, framed as "how we're building a continuous improvement culture where everyone is empowered to make things better every day." This implicitly grades the prior organizational structure as the source of execution failure — a sharper indictment than Q3's general dissatisfaction. It also commits to eliminating stranded TSA costs by end of 2027.

R&D commitment hardened. Q3 framed innovation as one of three priorities. This quarter Hider committed to "continued investment in R&D at or above historical levels" — meaning the FY2026 margin pressure is not getting offset by R&D cuts. That is the right strategic answer for a 5-year horizon and the wrong tactical answer for 2026 EPS, and management is choosing the former without apology.

Recurring themes management leaned on this quarter:

Organizational de-layering and accountability restructuring to simplify decision-makingStructural demand shift to 'new baseline' in IV solutions post-Hurricane HeleneMulti-quarter absorption headwinds and inventory destocking burdenElevated R&D investment to drive innovation despite margin pressureBack-half weighted recovery narrative dependent on cost actions bearing fruitBalance sheet deleveraging as primary cash deployment priority

Risks management surfaced:

Novum LDP ship-and-install hold expected to remain 'for the full year'Continued IV solutions demand depression from clinical practice changes post-Hurricane HeleneTariff headwind of $40 million year-over-year despite mitigation actionsInjectables and anesthesia softness from IV push utilization trends continuing into first half 2026Macroeconomic uncertainty affecting hospital capital spending despite no current slowdown observed

Q&A highlights

David Roman · Goldman Sachs

How is Baxter ensuring business sustainability amid strategic review, innovation catch-up, and deleveraging? How is management gaining visibility for forecasting given competitive dynamics?

Andrew emphasized customer engagement showing Baxter is essential, outlined stabilization priorities (accountability, balance sheet strengthening, continuous improvement), and discussed GPS program for disciplined operating rhythm. Joel highlighted GPS's structured approach to demand planning, cross-functional alignment, and daily/weekly operating mechanisms to reduce volatility and improve forecast accuracy.

Baxter touches over 350 million patients per yearGPS launched to improve forecasting accuracyConnect360 and Dynamo Stretcher platform launched40 basis points remaining TSA impact in 2025 on track

Vijay Kumar · Evercore ISI

Have you communicated to customers that Novum ship hold will remain in place for the full year? Are customers willing to wait? What has changed in the operating model and how will it impact free cash flow?

Andrew stated customers can continue using Novum per existing instructions with mitigating actions, Baxter has strong pump portfolio alternatives (Spectrum LVP, new IQX platform), and will launch Peerview early Q2. Described new operating model as de-layering, removing segment management, embedding functions directly into businesses to eliminate decision-making barriers. Joel confirmed 2026 free cash flow expected to improve vs 2025 driven by working capital and absence of one-time 2025 hits; earnings skewed to H2 due to structural impacts and manufacturing adjustments.

Novum ship hold continues; customers using device per existing instructions and mitigating actionsSpectrum with IQX platform launched; Peerview launching early Q2Operating model de-layered at top; segment management removed2026 free cash flow expected to improve vs 2025

Robbie Marcus · JPMorgan

Can Baxter grow earnings in 2027 as TSAs roll off? What explains Q4 gross and operating margin underperformance, and what should guide Q1 and 2026 cadence expectations?

Joel stated 2027 earnings growth anticipated but no specific guidance issued; TSAs drop off early 2027 with full elimination by end of 2027. Provided detailed Q1 headwinds: seasonality vs Q4, 150 bps one-time distributor build impact (~$40-50M), Novum customer behavior uncertainty, lower drug compounding growth (Q4 18% not sustainable), absorption headwinds from 2025 inventory capitalization, continued injectables/anesthesia softness, and incremental interest expense in Q1.

2027 earnings growth anticipated but not forecastedTSAs majority roll off early 2027; fully eliminated by end of 2027Q4 drug compounding grew 18%; Q1 expected lowerOne-time distributor build impact approximately $40-50 million in Q1

Larry Beagleson · Wells Fargo

What drove Q4 gross margin decline (tariffs, mix, reclassifications, one-time items)? How much lower will 2026 gross margin be vs 2025? Why retain low-margin compounding business that hurts overall mix?

Joel attributed Q4 margin pressure to unfavorable product/geographic mix, higher manufacturing and supply costs (labor-to-volume misalignment, pharma challenges), and ~$40M non-recurring items. Noted 2026 will have H1 headwinds (inventory capitalization rollout, tariffs, seasonality, ICT absorption) with H2 recovery from structural cost takeout and manufacturing labor alignment. Andrew defended pharma/compounding synergy with ITT (common customers, call points), highlighted operational execution improvements underway, noted supplier challenge being worked through, acknowledged mixed impact on margins but emphasized compounding's fastest cash cycle benefit.

~$40 million non-recurring items in Q4 affecting gross and operating marginsUnfavorable product and geographic mix in Q4Pharma operating margin 9% in full year, lower in Q4Compounding business: fastest growing but low margin; fastest cash cycle in company

Travis Steed · Bank of America

How should Q1 revenue and margins be modeled? What percent of 2026 earnings falls in Q1 vs H2? Is there assumption of share gains or losses in infusion pumps? Was the $50M sequential increase in OUS Care and Connectivity Solutions one-time?

Joel reiterated Q1 is most challenging quarter due to: volume/seasonality, Novum customer behavior uncertainty, continued pharma margin challenges, absorption headwinds from 2025 inventory capitalization, interest expense kicking in. Did not provide specific quarterly guidance but characterized H1 as pressure period with H2 improvement. Andrew addressed infusion pump competition: noted Spectrum is 'workhorse,' continues innovation, now interfaces with Novum syringe, confident in competitive position. On OUS Care/Connectivity Solutions: attributed $50M sequential growth to strong business fundamentals, good order book, competitive wins, improved performance outside U.S.; denied one-time items.

Q1 identified as most challenging quarter with multiple headwindsNovum customer behavior uncertainty continues into 2026Spectrum described as 'workhorse' in infusion pump marketSpectrum now interfaces with Novum syringe pump

Answers to last quarter's watch list

Novum LVP resolution timeline — Worse than feared. Management now explicitly states the ship-and-install hold "will remain in place for the full year" 2026 with no FDA submission date, no corrective action timeline, and no customer retention metrics disclosed. The customer attrition window is now extended through 2026.
Resolved negatively
Q4 operational growth vs. -2% guide — Clean beat. Operational growth came in +3% vs. -2% guided, a 5pp positive surprise driven by "more modest" Novum return impact and IV solutions stabilization. This suggests the -2% Q3 reset was meaningfully conservative, but the bigger signal is that FY2026 is now guided to organic flat, so the Q4 beat does not extrapolate.
Resolved positively
MPT segment growth in Q4 — Reversed from -1% in Q3 to +6% reported in Q4, with Advanced Surgery +12% and ITT +4%. The segment can grow when Novum return pressure abates. But with FY2026 organic flat overall and Novum hold extended, MPT growth in 2026 will depend on Advanced Surgery and IV solutions stability, not on Novum returning. Status: Resolved positively (Q4 only)
Adj. operating margin trajectory — Worse. FY2026 adj. operating margin guide of 13–14% is ~100–150bps below the FY2025 ~14.5% achieved, and Q4 adj. operating income of $352M implies the run-rate exited 2025 already pressured. ~$40M of non-recurring Q4 items obscured the underlying deterioration.
Resolved negatively
Dividend cut cash deployment — Management reiterated balance sheet deleveraging as primary cash priority and confirmed FY2026 free cash flow will improve vs FY2025, but specific net debt figures and progress against the end-2026 3x leverage target were not disclosed on the print.
Continue monitoring
Investor day timing and content — Postponed. Hider explicitly said "we have decided to hold off on our investor day," removing the catalyst Q3 management had pointed investors toward for strategic clarity. Portfolio rationalization details (divestitures, M&A) remain undisclosed.
Resolved negatively

What to watch into next quarter

Q1 2026 adj. EPS and operational growth — management has flagged Q1 as the "most challenging quarter" with ~$40–50M one-time distributor build, inventory absorption, tariffs, and interest expense layering. A Q1 print that requires H2 EPS to exceed $1.10+ to hit the $1.85–$2.05 FY range puts the back-half-weighted thesis under immediate pressure.

Novum corrective action filing — any FDA submission, 510(k) update, or specific resolution milestone before year-end 2026; absence of any of these confirms the hold extends into 2027 and forces a downward reset of MPT's structural growth rate.

U.S. operational sales trajectory — U.S. went -1% operational in Q4 while international was +8%. Watch whether U.S. inflects positive in any of the next two quarters; sustained U.S. contraction with international carrying the model is a fragile structure.

Adj. operating margin run-rate — Q1 will trough; watch Q2 for sequential improvement and confirmation that H2 13–14% range is achievable. A Q1 margin below 12% with no clear path back makes the FY guide aspirational.

Tariff mitigation execution — net $80M FY2026 tariff impact (~$40M YoY headwind) assumes mitigating actions land; watch for any commentary that mitigation is slipping, which would erode EPS further within the existing range.

Free cash flow conversion in H1 — management committed to FY2026 FCF improvement vs FY2025 but flagged H2 weighting; if H1 FCF lags meaningfully, the 3x leverage target by end-2026 slips again.

Sources

  1. Baxter International Q4 2025 press release / 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/10456/000162828026007474/bax-20260212xex991.htm
  2. Baxter International Q4 2025 earnings call prepared remarks and Q&A
  3. Tapebrief Q3 FY2025 BAX coverage (prior watch list and guide baseline)
  4. Tapebrief Q2 FY2025 BAX coverage (multi-quarter tone arc)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.